Emplicure AB Interim Report Q1 2023

2023-05-09 05:58


  • Net sales amounted to MSEK 0.0 (0.0)
  • Operating loss (EBIT) amounted to MSEK -6.3 (-7.3)
  • Net loss amounted to MSEK -6.8 (-7.3)
  • Net cash flow amounted to MSEK -6.0 (-5.6)
  • EPS before and after dilution amounted to SEK -0.26 (-0.36)


From this report and onwards, Emplicure will present the quarterly financial reports in English only.

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on May 9, 2023 at 07:58 CET

For additional information, please contact

Håkan Engqvist

Phone: +46 702 569 500
Email: hakan.engqvist@emplicure.com

Erik Magnusson

Phone: +46 708 565 245
Email: erik.magnusson@emplicure.com

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

The following documents can be retrieved from beQuoted
Emplicure-Q123 ENG FINAL.pdf

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

Do you want to know more?